Paul W. Manley

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Ellen Weisberg, Paul W. Manley, Werner Breitenstein et al. · Cancer Cell · 2005 · 1.5K citations · Full text

Pharmacy, Medicinal Chemistry, Molecular Biology +6

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

Hagop M. Kantarjian, Francis J. Giles, Lydia Wunderle et al. · New England Journal of Medicine · 2006 · 1.3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

<i>In vitro</i> Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

Thomas O’Hare, Denise K. Walters, Eric P. Stoffregen et al. · Cancer Research · 2005 · 1K citations · Full text

Medicine, Oncology, Pharmacology +10

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412

Ellen Weisberg, Christina Boulton, Louise Kelly et al. · Cancer Cell · 2002 · 602 citations · Full text

Medicine, Oncology, Pharmacology +14

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

Jianming Zhang, Francisco Adrián, Wolfgang Jahnke et al. · Nature · 2010 · 599 citations

Pharmacy, Medicinal Chemistry, Pharmacology +14